Study of Denikitug with immunotherapy or chemotherapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called denikitug, given alone or combined with other cancer treatments, for patients with advanced colorectal cancer that hasn't responded to previous treatments. The goal is to help people whose cancer has a specific genetic profile (MSS) that doesn't respond well to standard immunotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Advanced colorectal cancer that cannot be surgically removed, has come back, or has spread to other parts of the body
- Cancer cells must have a specific genetic pattern called MSS (microsatellite stable) or pMMR, confirmed by laboratory testing
- You have received 1–2 previous treatment regimens for advanced cancer, including certain chemotherapy drugs
- Your cancer has grown or worsened during or after your most recent treatment
- Good overall health and ability to perform daily activities with minimal assistance (ECOG score 0–1)
- Adequate heart, liver, and kidney function based on recent blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs for people with a specific type of colorectal cancer (MSS, or microsatellite stable) that has stopped responding to standard chemotherapy. The goal is to see if this new treatment can shrink tumors or slow the cancer's growth.
This trial tests whether a new drug called telisotuzumab adizutecan, given with bevacizumab, works better than the current standard treatment for colorectal cancer that has spread and stopped responding to previous chemotherapy. The goal is to see if this new combination helps patients live longer.
This trial tests a sequence of treatments for people with a specific type of advanced colorectal cancer (called pMMR or MSS) that has not responded to earlier therapies. Patients first receive an immunotherapy combination (pembrolizumab plus a personalized dendritic cell vaccine) followed by a chemotherapy pill (trifluridine/tipiracil) plus bevacizumab. The goal is to see if this sequence can help control the cancer.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a new approach for advanced colorectal cancer that has spread and is no longer responding to standard chemotherapy. It combines two types of radiation (one high dose, one low dose) with an immunotherapy drug and a targeted therapy (TKI) to see if this can help shrink tumors and improve outcomes.
This trial tests a mix of three drugs (sintilimab, bevacizumab, and decitabine) for people with advanced colorectal cancer that has a stable or low amount of genetic change. It’s for those whose cancer has grown after at least two prior treatments, and who have not had immunotherapy before.
Hear when a new Advanced Microsatellite Stable Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.